The effect of a serum containing acetyl hexapeptide‐8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies

OBJECTIVE: This study aimed to explore the anti-skin aging efficacy of a novel serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate, gluconolactone, niacinamide and laminaria extract through one ex-vivo study and two clinical studies. METHODS: In ex-vivo study, skin samples were exposed to the serum (Formula 1) and its active ingredient combinations (Formula 2). Biomarkers including matrix metalloproteinase-1, elastic fibres and collagen types I, III, IV and XVII content were analyzed to evaluate the efficacy. In clinical study 1 (n = 50), the Formula 1's efficacy in reducing static wrinkles and improving skin quality was examined, while study 2 (n = 42) focused on its efficacy against dynamic wrinkles. RESULTS: Formula 1 significantly increased levels of anti-aging biomarkers including elastic fibres, collagen fibres, etc. Meanwhile, Formula 1 significantly improved static wrinkle appearance within the first week, with mean clinical scoring from 35% to 69% for various types of wrinkles after 12 weeks of use (all p < 0.001). The clinical scoring for dynamic wrinkles improved by 10%-13% (all p < 0.001). Additionally, significant improvements were observed in skin quality, indicated by clinical scoring changes of smoothness (30%), radiance (27%), skin pore (43%), elasticity (33%) and firmness (36%) (all p < 0.001). CONCLUSION: The serum demonstrates significant anti-aging effects, effectively improving static and dynamic wrinkles and skin quality.